In this episode we will be speaking with Mr. Frank McEnulty, Chief Executive Officer, President and Director of Cell MedX Corp. as well as Dr. John Sanderson, their Chief Medical Officer. Mr. McEnulty discusses the company's innovative approach to treating diabetes as well as the primary driver's for their success, the economics of E-Balance technology as well as near term catalysts investors can look forward to in coming quarters. Dr. Sanderson discusses the underlying science behind their technology, how e-Balance is different from other solutions on the market and comments on when a commercial product will be ready. They trade under ticker symbol CMXC.